SEARCH

SEARCH BY CITATION

References

  • 1
    Centers for Disease Control and Prevention. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR 1994; 43: 117.
  • 2
    Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 17251730.
  • 3
    Ojo AO, Hanson JA, Meier-Kriesche H et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589597.
  • 4
    Ahuja TS, Grady J, Kahn S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am J Nephrol 2002; 13: 18891893.
  • 5
    Abbott KC, Swanson SJ, Agodoa LYC, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 16331639.
  • 6
    Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 16221629.
  • 7
    US Renal Data System, URSDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004: 1627.
  • 8
    2004 Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994–2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI.
  • 9
    Hadler SC, Francis DP, Maynard JE et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209214.
  • 10
    Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 5—Working with Markov processes. Med Decis Making 1997; 17: 152159.
  • 11
    Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (The ‘DEALE’). II. Use in medical decision-making. Am J Med 1982; 73: 889897.
  • 12
    Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 3—Estimating probabilities and utilities. Med Decis Making 1997; 17: 136141.
  • 13
    Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 12531258.
  • 14
    Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289: 959962.
  • 15
    Busch MP, Watanabe KK, Smith JW, Hermansen SW, Thomson RA. False-negative testing errors in routine viral marker screening of blood donors. Transfusion 2000; 40: 585589.
  • 16
    Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate window period model. Transfusion 2002; 42: 966972.
  • 17
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recommendation and Reports 1998; 47: 139.
  • 18
    Gaston RS, Danovitch GM, Adams PL et al. The report of a national conference on the wait list for kidney transplantation. Am J Transplant 2003; 3: 775785.
  • 19
    Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 5261.
  • 20
    Niu MT, Coleman PJ, Alter MJ. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis 1993; 22: 568573.
  • 21
    Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recommendations and Reports. 2001; 50; 143.
  • 22
    Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004; 4(Suppl 10): 7282.
  • 23
    Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR 2003; 52: 136.
  • 24
    Catania JA, Coates TJ, Stall R et al. Prevalence of AIDS-related risk factors and condom use in the United States. Science 1992; 258: 11011106.
  • 25
    McQuillan GM, Ezzati-Rice TM, Siller AB, Visscher W, Hurley P. Risk behavior and correlates of risk for HIV infection in the Dallas County Household HIV Survey. Am J Public Health 1994; 84: 747753.
  • 26
    Blattner WA, O'Brien TR, Mueller NE. Retroviruses—Human immunodeficiency virus, chapter 24. In:  EvansAS, KaslowRA, eds. Viral infections of humans—Epidemiology and control, 4th Ed. New York :Plenum Medical Book Company, 1997: 713783.
  • 27
    Quan VM, Steketee RW, Valleroy L, Weinstock H, Karon J, Janssen R. HIV incidence in the United States, 1978–1999. JAIDS 2002; 31: 188201.
  • 28
    Karon JM, Fleming PL, Steketee RW, DeCock KM. HIV in the United States at the turn of the century: An epidemic in transition. Am J Public Health 2001; 91: 10601068.
  • 29
    Kellogg TA, McFarland W, Perlman JL et al. HIV incidence among repeat HIV testers at a county hospital, San Francisco, California, USA. JAIDS 2001; 28: 5964.
  • 30
    Des Jariais DC, Diaz T, Perlis T et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C Virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157: 467471.
  • 31
    Villano SA, Vlahaov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997; 35: 32743277.
  • 32
    Thorpe LE, Ouellet LJ, Hershow R et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155: 645653.
  • 33
    Garfein RS, Doherty MCER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18(Suppl 1): S11S19.
  • 34
    Centers for Disease Control and Prevention. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men—Five US cities, June 2004—April 2005. MMWR 2005; 54; 597605.
  • 35
    Centers for Disease Control and Prevention. HIV incidence among young men who have sex with men—Seven US cities 1994–2000. MMWR 2001; 50; 440444.
  • 36
    Hammer GP, Kellogg TA, McFarland WC et al. Low incidence and prevalence of hepatitis C virus infection among sexually active non-intravenous drug-using adults, San Francisco, 1997–2000. Sex Transm Dis 2003; 30: 919924.
  • 37
    Rauch A, Rickenbach M, Weber R et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: The Swiss HIV Cohort Study. Clin Infect Dis 2005; 41: 395402.
  • 38
    Onorato IM, Klaskala W, Morgan WM, Withum D. Prevalence, incidence, and risks for HIV-1 infection in female sex workers in Miami, Florida. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 395400
  • 39
    Ghys PD, Diallo MO, Ettiegne-Traore V et al. Effect of interventions to control sexually transmitted disease on the incidence of HIV infection in female sex workers. AIDS 2001; 15: 14211431.
  • 40
    Macalino GE, Vlahov D, Sanford-Colby S et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health 2004; 94: 12181223.
  • 41
    Horsburgh CR, Jarvis JQ, McArthur T, Ignacio T, Stock P. Seroconversion to human immunodeficiency virus in prison inmates. Am J Public Health 1990; 80: 209210.
  • 42
    Brewer TF, Vlahov D, Taylor E, Hall D, Munoz A, Polk BF. Transmission of HIV-1 within a statewide prison system. AIDS 1988; 2: 363367.
  • 43
    Vlahov D, Nelson KE, Quinn TC, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993; 9: 566569.
  • 44
    Centers for Disease Control and Prevention. HIV prevalence trends in selected populations in the United States: Results from National Serosurveillance, 1993–1997. Atlanta: Centers for Disease Control and Prevention; 2001: 151.
  • 45
    Thorpe LE, Ouellet LJ, Levy RJ, Williams IT, Monterroso ER. Hepatitis C virus infection: Prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis 2000; 182: 15881594.
  • 46
    McKeganey NP. Prostitution and HIV: What do we know and where might research be targeted in the future? AIDS 1994; 8: 12151226.
  • 47
    Centers for Disease Control and Prevention. Antibody to human immunodeficiency virus in female prostitutes. MMWR 1987; 36: 157161.
  • 48
    Wu JC, Lin HC, Jeng FS, Ma GY, Lee SD, Sheng WY. Prevalence, infectivity, and risk factor analysis of hepatitis C virus infection in prostitutes. J Med Virol 1993; 39: 312317
  • 49
    Tabet SR, Palmer DL, Wiese WH, Voorhees RE, Pathak DR. Seroprevalence of HIV-1 and hepatitis B and C in prostitutes in Albuquerque, New Mexico. Am J Public Health 1992; 82: 11511154.
  • 50
    Hammett TM, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releasees from US correctional facilities, 1997. Am J Public Health 2002; 92: 17891794.
  • 51
    Centers for Disease Control and Prevention. Diagnosis if HIV AIDS—32 States, 2000–2003. MMWR 2004; 53; 11061110.
  • 52
    Centers for Disease Control and Prevention. HIV(AIDS Surveillance Report, 2003 (Vol. 15). Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2004: 145.
  • 53
    Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S65S.
  • 54
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 12711277.
  • 55
    Pereira BJG, Natov SN, Bouthot BA et al. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998; 53: 13741381.
  • 56
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: Meta-analysis of observational studies. Am J Transplant 2005; 5: 14521461.
  • 57
    Bozzette SA, Joyce G, McCaffrey DF et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817823.
  • 58
    Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moor RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963969.
  • 59
    Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med 2001; 161: 22312237.
  • 60
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855865.
  • 61
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228237.
  • 62
    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866874.
  • 63
    Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235242.
  • 64
    Russell JD, Beecroft ML, Ludwin D, Churchill DN. The quality of life in renal transplantation—A prospective study. Transplantation 1992; 54: 656660.
  • 65
    Whiting JF for The Transplant Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation 2000; 70: 11151121.
  • 66
    Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV(AIDS. Med Decis Making 2002; 22: 475481.
  • 67
    Sanders GD, Bayoumi AM, Sundaram V et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 2005; 352: 570585.
  • 68
    Chong AKY, Gulamhussein A, Heathcote J et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630638.
    Direct Link:
  • 69
    Sherman KE, Sherman SN, Chenier T, Tsevat J. Health values of patients with chronic hepatitis C infection. Arch Intern Med 2004; 164: 23772382.